Use of vecuronium to prevent suxamethonium-induced myalgia after ECT.
Herriot
P M
PM
Cowain
T
T
McLeod
D
D
D000328:Adult; D003866:Depressive Disorder / Q000628:therapy; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D009120:Muscle Cramp / Q000139:chemically induced / Q000517:prevention & control*; D009467:Neuromuscular Depolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D011229:Preanesthetic Medication; D013390:Succinylcholine / Q000008:administration & dosage / Q000009:adverse effects*; D014673:Vecuronium Bromide / Q000008:administration & dosage*
D009467:Neuromuscular Depolarizing Agents; D014673:Vecuronium Bromide; D013390:Succinylcholine